Advances in essential thrombocythemia with Drs. Kuykendall, Tremblay

In this episode of the SOHO Insider podcast, Douglas Tremblay discusses how to approach the treatment of essential thrombocythemia.

by Leah Sherwood
January 15, 2026

Registration now open for SOHO 2026, receive early bird registration rates until June 10

SOHO Insider Editors January 14, 2026

Registration is now officially open for the Fourteenth Annual Meeting of the Society of Hematologic Oncology. The event is scheduled for September 9 through September 12 at the George R. Brown Convention Center in Houston, Texas. SOHO 2026 will be held as a hybrid event to provide flexible participation options including in-person attendance, virtual access, and on-demand viewing.

Read More ➔

Chase with his family and newborn grandchild.

‘A stretch of normal life’ as myeloma patients enter uncharted era

Leah Sherwood January 13, 2026

How one patient traveled to China to pursue an experimental therapy that changed what was possible in multiple myeloma.

Read More ➔

Dr. Gwen Nichols, of Blood Cancer United, talks financial toxicity in blood cancer care

Leah Sherwood January 12, 2026

Gwen Nichols, MD, chief medical officer of Blood Cancer United, discusses generational financial toxicity in oncology, particularly in pediatric acute leukemia care, and the critical

Read More ➔

Dr. Thomas Martin interviews 1st US patient treated with cilta-cel

Leah Sherwood January 9, 2026

Society of Hematologic Oncology Insider news

Dr. Thomas Martin interviews 1st US patient treated with cilta-cel

00:00 / 00:09:48

In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient Craig Chase,

Read More ➔

Earlier lines of cilta-cel linked to better immune fitness in myeloma

Leah Sherwood January 8, 2026

Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, discusses the ASH 2025 abstract titled, “Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study.”

Read More ➔